Companies · Pharma
Australia · Pharma
Diligence memoA one-page analyst read on Orion Pharma — recommendation, valuation, rhythm, risks.→Orion Pharma: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Orion Pharma is one of 310 Pharma companies tracked from Australia. By capital raised it ranks in the long tail (ahead of 16% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
Australian company.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 16% of sector peers (real $). Modeled value above 16% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| 1200 Pharma LLC | Pharma | Series A | $14.1M | $13.2M | same sector |
| A28 Therapeutics, Inc. | Pharma | Seed | $1.9M | $31.6M | same sector |
| AbInitio Bio | Pharma | — | — | — | same sector |
| Acanna Therapeutics, Inc. | Pharma | Pre-Seed | $1.0M | $16.0M | same sector |
| Advanced Cardiac Therapeutics Inc | Pharma | Series C | $64.1M | $1.6B | same sector |
| ADvantage Therapeutics, Inc. | Pharma | Series A | $19.0M | $111.2M | same sector |
| AeroRx Therapeutics, Inc. | Pharma | Series A | $10.4M | $30.7M | same sector |
| Affect Therapeutics, Inc. | Pharma | Series B | $24.6M | $232.4M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Orion Biotechnology Canada Ltd. | Biotechnology | Series A | $3.9M | 84% |
| Bio South African company. | Biotech / Pharma | — | — | 83% |
| Celestial Therapeutics Inc. | Biotechnology | Seed | $3.5M | 82% |
| Orionis Biosciences LLC | Biotechnology | Series B | $782.6M | 80% |
| Athena Therapeutics, LLC | Biotechnology | Seed | $43.4M | 80% |
| Odyssey Therapeutics, Inc. | Biotechnology | Series D+ | $1.7B | 80% |
| Cosmos Pharmaceuticals, LLC | Biotech / Pharma | Pre-Seed | $1.6M | 80% |
| Phoenix Biotechnology Inc | Pharmaceuticals | Series A | $147.9M | 79% |
See where Orion Pharma sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Orion Pharma, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.